Moderna Named No.1 Impactful Company, Gains EU Approval for mCOMBRIAX® and Expands Partnerships
Moderna topped TIME’s 2026 World's Most Impactful Companies list as a pioneer of mRNA technology, reflecting its leadership across infectious disease, oncology and rare disease pipelines. In 2026 it secured European approval for its fourth product mCOMBRIAX® and expanded manufacturing partnerships with UK, Canada and Australia.
1. TIME Names Moderna Top Impactful Company
Moderna secured the top spot on TIME’s 2026 list of the World's Most Impactful Companies, highlighting its pioneering role in mRNA technology and its broad pipeline encompassing infectious diseases, oncology and rare diseases.
2. European Approval for mCOMBRIAX® and Manufacturing Partnerships
In early 2026 the company obtained European approval for mCOMBRIAX®, its fourth product combining flu and COVID vaccines, while expanding manufacturing partnerships in the UK, Canada and Australia to boost pandemic readiness and capacity.
3. AI Platform Aims to Accelerate Hantavirus Vaccine Development
Moderna is deploying its generative AI platform to accelerate development of a hantavirus vaccine, targeting a process that traditionally spans 10 to 15 years and costs billions, in an effort to shorten timelines for emerging infectious diseases.